Ryan P - Search Results

1

Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe.

Morales DR, Ostropolets A, Lai L, Sena A, Duvall S, Suchard M, Verhamme K, Rjinbeek P, Posada J, Ahmed W, Alshammary T, Alghoul H, Alser O, Areia C, Blacketer C, Burn E, Casajust P, You SC, Dawoud D, Golozar A, Gong M, Jonnagaddala J, Lynch K, Matheny M, Minty E, Nyberg F, Uribe A, Recalde M, Reich C, Scheumie M, Shah K, Shah N, Schilling L, Vizcaya D, Zhang L, Hripcsak G, Ryan P, Prieto-Alhambra D, Durate-Salles T, Kostka K. Morales DR, et al. Among authors: ryan p. J Asthma. 2023 Jan;60(1):76-86. doi: 10.1080/02770903.2021.2025392. Epub 2022 Feb 11. J Asthma. 2023. PMID: 35012410

2

Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases.

Reich C, Ryan PB, Stang PE, Rocca M. Reich C, et al. J Biomed Inform. 2012 Aug;45(4):689-96. doi: 10.1016/j.jbi.2012.05.002. Epub 2012 Jun 7. J Biomed Inform. 2012. PMID: 22683994 Free article.

3

Interpreting observational studies: why empirical calibration is needed to correct p-values.

Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D. Schuemie MJ, et al. Stat Med. 2014 Jan 30;33(2):209-18. doi: 10.1002/sim.5925. Epub 2013 Jul 30. Stat Med. 2014. PMID: 23900808 Free PMC article.

4

Multiple self-controlled case series for large-scale longitudinal observational databases.

Simpson SE, Madigan D, Zorych I, Schuemie MJ, Ryan PB, Suchard MA. Simpson SE, et al. Biometrics. 2013 Dec;69(4):893-902. doi: 10.1111/biom.12078. Epub 2013 Oct 11. Biometrics. 2013. PMID: 24117144

5

Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.

Suchard MA, Zorych I, Simpson SE, Schuemie MJ, Ryan PB, Madigan D. Suchard MA, et al. Drug Saf. 2013 Oct;36 Suppl 1:S83-93. doi: 10.1007/s40264-013-0100-4. Drug Saf. 2013. PMID: 24166226

6

A comparison of the empirical performance of methods for a risk identification system.

Ryan PB, Stang PE, Overhage JM, Suchard MA, Hartzema AG, DuMouchel W, Reich CG, Schuemie MJ, Madigan D. Ryan PB, et al. Drug Saf. 2013 Oct;36 Suppl 1:S143-58. doi: 10.1007/s40264-013-0108-9. Drug Saf. 2013. PMID: 24166231

7

Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Reich CG, Ryan PB, Schuemie MJ. Reich CG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S181-93. doi: 10.1007/s40264-013-0111-1. Drug Saf. 2013. PMID: 24166234

8

The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Reich CG, Ryan PB, Suchard MA. Reich CG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S195-204. doi: 10.1007/s40264-013-0112-0. Drug Saf. 2013. PMID: 24166235

9

Medication-wide association studies.

Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Ryan PB, et al. CPT Pharmacometrics Syst Pharmacol. 2013 Sep 18;2(9):e76. doi: 10.1038/psp.2013.52. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 24448022 Free PMC article.

10

Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model.

Matcho A, Ryan P, Fife D, Reich C. Matcho A, et al. Among authors: ryan p. Drug Saf. 2014 Nov;37(11):945-59. doi: 10.1007/s40264-014-0214-3. Drug Saf. 2014. PMID: 25187016 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,553 results

Search Page

Filters